New preclinical study shows antibody therapy could offer treatment path for genetic form of ALS
Neurimmune is a biopharmaceutical company translating B-cell derived genetic information of human immune repertoires into antibody therapeutics.
Neurimmune discovered aducanumab together with a team of researchers at the University of Zurich and licensed it to Biogen. Neurimmune collaborates on aducanumab with Biogen who co-develops it with Eisai.
Aducanumab is a human monoclonal antibody removing beta amyloid in brains of patients with Alzheimer’s disease. Based on large Phase 3 study results showing clinical benefit, Biogen plans regulatory filing for aducanumab in Alzheimer’s disease.
Neurimmune’s pipeline comprises drug candidates for diseases of the central nervous system and related protein aggregation diseases. With its Reverse Translational Medicine technology platform, Neurimmune is able to discover human antibodies against virtually any pharmacological target structure in the human body.
